Organon & Co.

OGNNYSECIK 1821825Healthcare / Drug Manufacturersfiscal year ends December27 quarters since 2020

Revenue, Q3 FY2026
$1.6B
−1.7% on Q3 FY2025
Net income
$164M
+2.5% on Q3 FY2025
Free cash flow
$326M
+49.5% on Q3 FY2025
Diluted EPS
$0.60
−1.6% on Q3 FY2025
Revenue, TTM
$6.1B
trailing four quarters
Net margin, TTM
3.5%
net income $213M
Free cash flow, TTM
$675M
$843M less $168M capex
Cash and equivalents
$1.5B
long-term debt $8.5B, Sep 30, 2026
Shares, 12-month change
+1.0%
263M shares, Sep 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
$20M
0.6% of market value
Market value
$3.7B
at the close, buybacks

Latest quarter Q3 FY2026, filed October 30, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, Organon & Co. reported revenue of $1.6B, −1.7% on Q3 FY2025, and net income of $164M (+2.5%). Free cash flow, operating cash flow less capital expenditures, was $326M ($370M less $44M). Diluted earnings per share were $0.60.

Share price

Daily candlesticks from November 18, 2024 to November 13, 2026, with each earnings release marked; a release after the close marks the day it came out, so its reaction is the next candle. See this earnings season for every company’s reaction.

OGN daily priceSplit-adjusted, US dollars; an earnings release
Nov 13, 2026O $13.90 · H $13.90 · L $13.88 · C $13.90 · 0.00% on the dayOver the range: +82.41%, Nov 14, 2025 to Nov 13, 2026
$5.20$7.50$9.79$12$14Nov 25Jan 26Apr 26Jun 26Sep 26Nov 26

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of October 30, 2026.

Revenue and net incomeRevenueNet income
−$500M$0$500M$1.0B$1.5B$2.0BQ4'22, Revenue: $1.5BQ4'22, Net income: $108MQ4'22Q1'23, Revenue: $1.5BQ1'23, Net income: $177MQ1'23Q2'23, Revenue: $1.6BQ2'23, Net income: $242MQ2'23Q3'23, Revenue: $1.5BQ3'23, Net income: $58MQ3'23Q4'23, Revenue: $1.6BQ4'23, Net income: $546MQ4'23Q1'24, Revenue: $1.6BQ1'24, Net income: $201MQ1'24Q2'24, Revenue: $1.6BQ2'24, Net income: $195MQ2'24Q3'24, Revenue: $1.6BQ3'24, Net income: $359MQ3'24Q4'24, Revenue: $1.6BQ4'24, Net income: $109MQ4'24Q1'25, Revenue: $1.5BQ1'25, Net income: $87MQ1'25Q2'25, Revenue: $1.6BQ2'25, Net income: $145MQ2'25Q3'25, Revenue: $1.6BQ3'25, Net income: $160MQ3'25Q4'25, Revenue: $1.5BQ4'25, Net income: −$205MQ4'25Q1'26, Revenue: $1.5BQ1'26, Net income: $146MQ1'26Q2'26, Revenue: $1.6BQ2'26, Net income: $108MQ2'26Q3'26, Revenue: $1.6BQ3'26, Net income: $164MQ3'26−$500M$0$500M$1.0B$1.5B$2.0BQ4'22, Revenue: $1.5BQ4'22, Net income: $108MQ4'22Q1'23, Revenue: $1.5BQ1'23, Net income: $177MQ1'23Q2'23, Revenue: $1.6BQ2'23, Net income: $242MQ2'23Q3'23, Revenue: $1.5BQ3'23, Net income: $58MQ3'23Q4'23, Revenue: $1.6BQ4'23, Net income: $546MQ4'23Q1'24, Revenue: $1.6BQ1'24, Net income: $201MQ1'24Q2'24, Revenue: $1.6BQ2'24, Net income: $195MQ2'24Q3'24, Revenue: $1.6BQ3'24, Net income: $359MQ3'24Q4'24, Revenue: $1.6BQ4'24, Net income: $109MQ4'24Q1'25, Revenue: $1.5BQ1'25, Net income: $87MQ1'25Q2'25, Revenue: $1.6BQ2'25, Net income: $145MQ2'25Q3'25, Revenue: $1.6BQ3'25, Net income: $160MQ3'25Q4'25, Revenue: $1.5BQ4'25, Net income: −$205MQ4'25Q1'26, Revenue: $1.5BQ1'26, Net income: $146MQ1'26Q2'26, Revenue: $1.6BQ2'26, Net income: $108MQ2'26Q3'26, Revenue: $1.6BQ3'26, Net income: $164MQ3'26−$500M$0$500M$1.0B$1.5B$2.0BQ4'22, Revenue: $1.5BQ4'22, Net income: $108MQ1'23, Revenue: $1.5BQ1'23, Net income: $177MQ1'23Q2'23, Revenue: $1.6BQ2'23, Net income: $242MQ3'23, Revenue: $1.5BQ3'23, Net income: $58MQ3'23Q4'23, Revenue: $1.6BQ4'23, Net income: $546MQ1'24, Revenue: $1.6BQ1'24, Net income: $201MQ1'24Q2'24, Revenue: $1.6BQ2'24, Net income: $195MQ3'24, Revenue: $1.6BQ3'24, Net income: $359MQ3'24Q4'24, Revenue: $1.6BQ4'24, Net income: $109MQ1'25, Revenue: $1.5BQ1'25, Net income: $87MQ1'25Q2'25, Revenue: $1.6BQ2'25, Net income: $145MQ3'25, Revenue: $1.6BQ3'25, Net income: $160MQ3'25Q4'25, Revenue: $1.5BQ4'25, Net income: −$205MQ1'26, Revenue: $1.5BQ1'26, Net income: $146MQ1'26Q2'26, Revenue: $1.6BQ2'26, Net income: $108MQ3'26, Revenue: $1.6BQ3'26, Net income: $164MQ3'26

Net income losses drawn in red.

Free cash flow
−$100M$0$100M$200M$300M$400MQ4'22, Free cash flow: $204MQ4'22Q1'23, Free cash flow: $68MQ1'23Q2'23, Free cash flow: −$44MQ2'23Q3'23, Free cash flow: $206MQ3'23Q4'23, Free cash flow: $318MQ4'23Q1'24, Free cash flow: $30MQ1'24Q2'24, Free cash flow: $300MQ2'24Q3'24, Free cash flow: $99MQ3'24Q4'24, Free cash flow: $335MQ4'24Q1'25, Free cash flow: $43MQ1'25Q2'25, Free cash flow: $181MQ2'25Q3'25, Free cash flow: $218MQ3'25Q4'25, Free cash flow: $96MQ4'25Q1'26, Free cash flow: $188MQ1'26Q2'26, Free cash flow: $65MQ2'26Q3'26, Free cash flow: $326MQ3'26−$100M$0$100M$200M$300M$400MQ4'22, Free cash flow: $204MQ4'22Q1'23, Free cash flow: $68MQ1'23Q2'23, Free cash flow: −$44MQ2'23Q3'23, Free cash flow: $206MQ3'23Q4'23, Free cash flow: $318MQ4'23Q1'24, Free cash flow: $30MQ1'24Q2'24, Free cash flow: $300MQ2'24Q3'24, Free cash flow: $99MQ3'24Q4'24, Free cash flow: $335MQ4'24Q1'25, Free cash flow: $43MQ1'25Q2'25, Free cash flow: $181MQ2'25Q3'25, Free cash flow: $218MQ3'25Q4'25, Free cash flow: $96MQ4'25Q1'26, Free cash flow: $188MQ1'26Q2'26, Free cash flow: $65MQ2'26Q3'26, Free cash flow: $326MQ3'26−$100M$0$100M$200M$300M$400MQ4'22, Free cash flow: $204MQ1'23, Free cash flow: $68MQ1'23Q2'23, Free cash flow: −$44MQ3'23, Free cash flow: $206MQ3'23Q4'23, Free cash flow: $318MQ1'24, Free cash flow: $30MQ1'24Q2'24, Free cash flow: $300MQ3'24, Free cash flow: $99MQ3'24Q4'24, Free cash flow: $335MQ1'25, Free cash flow: $43MQ1'25Q2'25, Free cash flow: $181MQ3'25, Free cash flow: $218MQ3'25Q4'25, Free cash flow: $96MQ1'26, Free cash flow: $188MQ1'26Q2'26, Free cash flow: $65MQ3'26, Free cash flow: $326MQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$3B$5B$8B$10BQ4'22, Cash and equivalents: $706MQ4'22, Long-term debt: $8.9BQ4'22Q1'23, Cash and equivalents: $459MQ1'23, Long-term debt: $8.7BQ1'23Q2'23, Cash and equivalents: $326MQ2'23, Long-term debt: $8.7BQ2'23Q3'23, Cash and equivalents: $414MQ3'23, Long-term debt: $8.6BQ3'23Q4'23, Cash and equivalents: $693MQ4'23, Long-term debt: $8.8BQ4'23Q1'24, Cash and equivalents: $575MQ1'24, Long-term debt: $8.7BQ1'24Q2'24, Cash and equivalents: $704MQ2'24, Long-term debt: $8.6BQ2'24Q3'24, Cash and equivalents: $763MQ3'24, Long-term debt: $8.7BQ3'24Q4'24, Cash and equivalents: $675MQ4'24, Long-term debt: $8.9BQ4'24Q1'25, Cash and equivalents: $547MQ1'25, Long-term debt: $8.9BQ1'25Q2'25, Cash and equivalents: $599MQ2'25, Long-term debt: $8.8BQ2'25Q3'25, Cash and equivalents: $672MQ3'25, Long-term debt: $8.8BQ3'25Q4'25, Cash and equivalents: $574MQ4'25, Long-term debt: $8.6BQ4'25Q1'26, Cash and equivalents: $1.1BQ1'26, Long-term debt: $8.6BQ1'26Q2'26, Cash and equivalents: $1.1BQ2'26, Long-term debt: $8.5BQ2'26Q3'26, Cash and equivalents: $1.5BQ3'26, Long-term debt: $8.5BQ3'26$0$3B$5B$8B$10BQ4'22, Cash and equivalents: $706MQ4'22, Long-term debt: $8.9BQ4'22Q1'23, Cash and equivalents: $459MQ1'23, Long-term debt: $8.7BQ1'23Q2'23, Cash and equivalents: $326MQ2'23, Long-term debt: $8.7BQ2'23Q3'23, Cash and equivalents: $414MQ3'23, Long-term debt: $8.6BQ3'23Q4'23, Cash and equivalents: $693MQ4'23, Long-term debt: $8.8BQ4'23Q1'24, Cash and equivalents: $575MQ1'24, Long-term debt: $8.7BQ1'24Q2'24, Cash and equivalents: $704MQ2'24, Long-term debt: $8.6BQ2'24Q3'24, Cash and equivalents: $763MQ3'24, Long-term debt: $8.7BQ3'24Q4'24, Cash and equivalents: $675MQ4'24, Long-term debt: $8.9BQ4'24Q1'25, Cash and equivalents: $547MQ1'25, Long-term debt: $8.9BQ1'25Q2'25, Cash and equivalents: $599MQ2'25, Long-term debt: $8.8BQ2'25Q3'25, Cash and equivalents: $672MQ3'25, Long-term debt: $8.8BQ3'25Q4'25, Cash and equivalents: $574MQ4'25, Long-term debt: $8.6BQ4'25Q1'26, Cash and equivalents: $1.1BQ1'26, Long-term debt: $8.6BQ1'26Q2'26, Cash and equivalents: $1.1BQ2'26, Long-term debt: $8.5BQ2'26Q3'26, Cash and equivalents: $1.5BQ3'26, Long-term debt: $8.5BQ3'26$0$3B$5B$8B$10BQ4'22, Cash and equivalents: $706MQ4'22, Long-term debt: $8.9BQ1'23, Cash and equivalents: $459MQ1'23, Long-term debt: $8.7BQ1'23Q2'23, Cash and equivalents: $326MQ2'23, Long-term debt: $8.7BQ3'23, Cash and equivalents: $414MQ3'23, Long-term debt: $8.6BQ3'23Q4'23, Cash and equivalents: $693MQ4'23, Long-term debt: $8.8BQ1'24, Cash and equivalents: $575MQ1'24, Long-term debt: $8.7BQ1'24Q2'24, Cash and equivalents: $704MQ2'24, Long-term debt: $8.6BQ3'24, Cash and equivalents: $763MQ3'24, Long-term debt: $8.7BQ3'24Q4'24, Cash and equivalents: $675MQ4'24, Long-term debt: $8.9BQ1'25, Cash and equivalents: $547MQ1'25, Long-term debt: $8.9BQ1'25Q2'25, Cash and equivalents: $599MQ2'25, Long-term debt: $8.8BQ3'25, Cash and equivalents: $672MQ3'25, Long-term debt: $8.8BQ3'25Q4'25, Cash and equivalents: $574MQ4'25, Long-term debt: $8.6BQ1'26, Cash and equivalents: $1.1BQ1'26, Long-term debt: $8.6BQ1'26Q2'26, Cash and equivalents: $1.1BQ2'26, Long-term debt: $8.5BQ3'26, Cash and equivalents: $1.5BQ3'26, Long-term debt: $8.5BQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed October 30, 2026.

Organon & Co. income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 30, 2026Q2 FY2026ended Jun 30, 2026filed Jul 31, 2026Q1 FY2026ended Mar 31, 2026filed May 4, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Nov 10, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 2, 2025Q4 FY2024ended Dec 31, 2024filed Feb 28, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue1,5741,5581,4601,5071,6021,5941,5131,592−1.7%
Cost of revenue705711677766745720672696−5.4%
Gross profit869847783741857874841896+1.4%
Research and development—————————
Selling, general and administrative421434424433415453420470+1.4%
Operating income—————————
Other income (expense)—————————
Pretax income255183213(148)243229101129+4.9%
Income tax9175675783841420+9.6%
Net income164108146(205)16014587109+2.5%
Diluted EPS ($)0.600.400.55—0.610.560.33—−1.6%
Diluted shares (millions)272270263—261260261——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed October 30, 2026.

Organon & Co. balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 30, 2026Q2 FY2026ended Jun 30, 2026filed Jul 31, 2026Q1 FY2026ended Mar 31, 2026filed May 4, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Nov 10, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 2, 2025Q4 FY2024ended Dec 31, 2024filed Feb 28, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents1,4551,1321,116574672599547675+116.5%
Short-term investments—————————
Total current assets5,3695,1114,9324,3524,7004,6184,3714,348+14.2%
Total assets13,40113,17812,99612,86713,55213,50013,15613,101−1.1%
Total current liabilities2,6522,6162,5002,3902,6792,7962,6152,718−1.0%
Long-term debt8,4858,4798,5538,6288,7838,7818,9368,860−3.4%
Total debt8,5548,5538,5698,6448,8288,8968,9568,880−3.1%
Total liabilities12,20812,17212,09312,11512,64612,76712,61412,629−3.5%
Stockholders’ equity1,1931,006903752906733542472+31.7%
Shares outstanding (millions)263263263260260260260258—

Positions at each period end. Long-term debt is the line the filer tags, with or without its current portion. Total debt is one definition across filers, built from filed lines: long-term debt with its current portion plus short-term borrowings, finance leases where the filer folds them into its debt line, operating leases never; it is blank where the tags do not add up to it. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed October 30, 2026.

Organon & Co. cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 30, 2026Q2 FY2026ended Jun 30, 2026filed Jul 31, 2026Q1 FY2026ended Mar 31, 2026filed May 4, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Nov 10, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 2, 2025Q4 FY2024ended Dec 31, 2024filed Feb 28, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow37010722514126422075390+40.2%
Capital expenditures4442374546393255−4.3%
Free cash flow (CFO − capex)326651889621818143335+49.5%
Depreciation and amortization—————————
Share repurchases—————————
Dividends paid56543107174+66.7%

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 24, 2026.

Income statement

Organon & Co. income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 28, 2025FY2023ended Dec 31, 2023filed Feb 26, 2024FY2022ended Dec 31, 2022filed Feb 27, 2023FY2021ended Dec 31, 2021filed Mar 21, 2022FY2020ended Dec 31, 2020filed Jun 21, 2021FY2019ended Dec 31, 2019filed Jun 21, 2021
Revenue6,2166,4036,2636,1746,3046,5327,777
Cost of revenue2,9032,6882,5152,2942,3822,1192,274
Gross profit3,3133,7153,7483,880———
Research and development————443210220
Selling, general and administrative1,7211,7601,8931,7041,6681,3561,443
Operating income———————
Other income (expense)———————
Pretax income4258076731,1221,5292,7523,696
Income tax238(57)(350)205178496390
Net income1878641,0239171,3512,1603,218
Diluted EPS ($)0.723.333.993.595.318.5212.69
Diluted shares (millions)261259256255254254254

Balance sheet

Organon & Co. balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 28, 2025FY2023ended Dec 31, 2023filed Feb 26, 2024FY2022ended Dec 31, 2022filed Feb 27, 2023FY2021ended Dec 31, 2021filed Mar 21, 2022FY2020ended Dec 31, 2020filed Jun 21, 2021FY2019ended Dec 31, 2019filed Jun 21, 2021
Cash and equivalents57467569370673712—
Short-term investments———————
Total current assets4,3524,3484,5083,9313,7603,567—
Total assets12,86713,10112,05810,95510,68110,109—
Total current liabilities2,3902,7182,9182,5122,5972,673—
Long-term debt8,6288,8608,7518,9059,1250—
Total debt8,6448,8808,7608,9219,1430—
Total liabilities12,11512,62912,12811,847———
Stockholders’ equity752472(70)(892)(1,508)5,4867,035
Shares outstanding (millions)260258256254254——

Cash flow statement

Organon & Co. cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 28, 2025FY2023ended Dec 31, 2023filed Feb 26, 2024FY2022ended Dec 31, 2022filed Feb 27, 2023FY2021ended Dec 31, 2021filed Mar 21, 2022FY2020ended Dec 31, 2020filed Jun 21, 2021FY2019ended Dec 31, 2019filed Jun 21, 2021
Operating cash flow700939799858———
Capital expenditures16217525119619225592
Free cash flow (CFO − capex)538764548662———
Depreciation and amortization361277236212195142333
Share repurchases———————
Dividends paid8829729429014500

Insider activity

Form 4 filings by officers, directors and 10% owners, November 16, 2024 to November 16, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$0
0 sales by 0 insiders; officers and directors $0
Bought, twelve months
$353K
1 purchases by 1 insider; officers and directors $353K
Sold, twelve months
$553K
2 sales by 2 insiders; officers and directors $553K

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Nov 7, 2026Drinane Juliana PapaHead of Mfg & Supplyoption exercise3,626$0.00—22,101Nov 10, 2026
Nov 7, 2026Drinane Juliana PapaHead of Mfg & Supplytax withholding1,242$13.87$17K20,859Nov 10, 2026
Nov 7, 2026Arjona Ferreira Juan CamiloHead of R&D & CMOoption exercise6,447$0.00—43,879Nov 10, 2026
Nov 7, 2026Arjona Ferreira Juan CamiloHead of R&D & CMOtax withholding2,314$13.87$32K41,565Nov 10, 2026
Nov 7, 2026Holzbaur LynetteSVP and Corporate Controlleroption exercise2,418$0.00—4,590Nov 10, 2026
Nov 7, 2026Holzbaur LynetteSVP and Corporate Controllertax withholding689$13.87$10K3,901Nov 10, 2026
Nov 5, 2026Holzbaur LynetteSVP and Corporate Controlleroption exercise3,038$0.00—3,038Nov 10, 2026
Nov 5, 2026Holzbaur LynetteSVP and Corporate Controllertax withholding866$13.83$12K2,172Nov 10, 2026
Aug 11, 2026Arjona Ferreira Juan CamiloHead of R&D & CMOoption exercise11,519$0.00—41,566Aug 12, 2026
Aug 11, 2026Arjona Ferreira Juan CamiloHead of R&D & CMOtax withholding4,134$13.62$56K37,432Aug 12, 2026
Aug 5, 2026Drinane Juliana PapaHead of Mfg & Supplyopen-market sale14,761$13.57$200K18,475Aug 5, 2026
May 6, 2026Holzbaur LynetteSVP and Corporate Controllerother46$0.00—26,448May 7, 2026
May 6, 2026Holzbaur LynetteSVP and Corporate Controlleropen-market sale26,448$13.35$353K0May 7, 2026
May 6, 2026Holzbaur LynetteSVP and Corporate Controlleropen-market buy26,448$13.35$353K52,851May 7, 2026
Mar 31, 2026Drinane Juliana PapaInterim Head of Mfg & Supplyoption exercise6,378$0.00—28,799Apr 2, 2026
Mar 31, 2026Drinane Juliana PapaInterim Head of Mfg & Supplytax withholding2,185$5.70$12K26,614Apr 2, 2026
Mar 31, 2026Drinane Juliana PapaInterim Head of Mfg & Supplyoption exercise10,073$0.00—36,687Apr 2, 2026
Mar 31, 2026Drinane Juliana PapaInterim Head of Mfg & Supplytax withholding3,451$5.70$20K33,236Apr 2, 2026
Mar 31, 2026Arjona Ferreira Juan CamiloHead of R&D & CMOoption exercise13,431$0.00—34,867Apr 2, 2026
Mar 31, 2026Arjona Ferreira Juan CamiloHead of R&D & CMOtax withholding4,820$5.70$27K30,047Apr 2, 2026
Mar 31, 2026Karp DanielExecutive VP, Corp. Dev.option exercise11,338$0.00—68,492Apr 2, 2026
Mar 31, 2026Karp DanielExecutive VP, Corp. Dev.tax withholding3,554$5.70$20K64,938Apr 2, 2026
Mar 31, 2026Karp DanielExecutive VP, Corp. Dev.option exercise6,715$0.00—71,653Apr 2, 2026
Mar 31, 2026Karp DanielExecutive VP, Corp. Dev.tax withholding2,105$5.70$12K69,548Apr 2, 2026
Mar 31, 2026Stahler Rachel AChief Information Officeroption exercise6,555$0.00—110,256Apr 2, 2026

Full insider history for Organon & Co., or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
Organon & Co., CIK 1821825 on EDGAR
Extract generated
November 16, 2026
Withheld
none
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: Revenues
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: not filed
Other income (expense): not filed
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: not filed
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total debt: LongTermDebt, noncurrent, noncurrent+current
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquireProductiveAssets, PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: not filed
Share repurchases: not filed
Dividends paid: PaymentsOfDividends

The data

The statements on this page as files, generated November 16, 2026.

JSON file
/data/financials/OGN.json